Last quarter (Q3 2024), VYNE Therapeutics's total revenue was $100.00K, a decrease of -12.28% from the same quarter last year. In Q3, VYNE Therapeutics's net income was $-12.16M. See VYNE Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 472.00K	$ 424.00K	$ 477.00K	$ 931.00K	$ 20.99M	$ 443.00K
Cost of Revenue	$ ―	$ ―	$ ―	$ 3.35M	$ 1.39M	$ ―
Gross Profit	$ 452.00K	$ 400.00K	$ 500.00K	$ 931.00K	$ 19.60M	$ 443.00K
Operating Expense	$ 38.19M	$ 29.68M	$ 34.77M	$ 39.84M	$ 133.08M	$ 96.32M
Operating Income	$ -37.70M	$ -29.26M	$ -34.30M	$ -38.91M	$ -252.55M	$ -95.87M
Net Non Operating Interest Income Expense	$ ―	$ ―	$ ―	$ -5.61M	$ -4.39M	$ -921.00K
Other Income Expense	$ -982.00K	$ 1.39M	$ 363.00K	$ 135.00K	$ -1.11M	$ 1.44M
Pretax Income	$ -33.94M	$ -27.87M	$ -33.93M	$ -44.66M	$ -255.83M	$ -98.23M
Tax Provision	$ -123.00K	$ -123.00K	$ 13.00K	$ -448.00K	$ -258.00K	$ -176.00K
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ -34.00M	$ -28.45M	$ -23.21M	$ -44.21M	$ -255.57M	$ -98.06M
Basic EPS	$ 3.40	$ -2.78	$ -7.28	$ 25.56	$ 141.84	$ -11.19
Diluted EPS	$ 3.40	$ -2.78	$ -7.28	$ 25.56	$ -135.54	$ 11.22
Basic Average Shares	$ 159.03M	$ 10.27M	$ 3.19M	$ 2.86M	$ 1.80M	$ 8.48M
Diluted Average Shares	$ 159.03M	$ 10.27M	$ 3.19M	$ 2.86M	$ 1.80M	$ 8.48M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ 38.19M	$ 29.68M	$ 34.77M	$ 82.79M	$ 134.47M	$ 96.32M
Net Income From Continuing And Discontinued Operation	$ -34.00M	$ -28.45M	$ -23.21M	$ -73.33M	$ -255.57M	$ -98.06M
Normalized Income	$ -9.30M	$ ―	$ ―	$ -41.90M	$ ―	$ ―
Interest Expense	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
EBIT	$ -37.70M	$ -29.26M	$ -34.30M	$ -39.05M	$ -251.44M	$ -97.31M
EBITDA	$ -38.20M	$ -29.26M	$ -34.22M	$ -38.94M	$ -251.09M	$ -96.91M

Currency in USD

VYNE Therapeutics Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing